What is Zacks Small Cap’s Estimate for COCP Q1 Earnings?
Stock analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for Cocrystal Pharma in a research ...
Analysts Offer Predictions for COCP Q3 Earnings
Equities research analysts at Zacks Small Cap issued their Q3 2025 earnings per share (EPS) estimates for Cocrystal Pharma in a research report issued to clients and investors on Tuesday, April 1st.
Cocrystal Pharma reports FY24 EPS ($1.72), consensus ($1.93)
Our novel, potent antiviral compounds for norovirus, influenza and coronavirus address critical gaps in global health where effective ...
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the 12 months ended December 31, 2024, and provides updates on its antiviral product pipeline, ...